Doxofylline

• Description:

  Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation) . Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm[1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Adenosine Receptor; Phosphodiesterase (PDE) ; Reactive Oxygen Species (ROS)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Doxofylline.html

• Purity:

  99.97

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

• Smiles:

  O=C(N1C)N(C)C2=C(N(CC3OCCO3)C=N2)C1=O

• Molecular Formula:

  C11H14N4O4

• Molecular Weight:

  266.25

• Precautions:

  H302

• References & Citations:

  [1]Jiao P, et al. The protective effect of doxofylline against lipopolysaccharides (LPS) -induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells. Artif Cells Nanomed Biotechnol. 2020 Dec;48 (1) :687-694. |[2]Riffo-Vasquez Y, et al. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014 Apr;27 (2) :170-8.|[3]Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10 (14) :2343-56.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [69975-86-6]